Home / Specialty Pharmacy (page 20)

Specialty Pharmacy

Geisinger Researchers Discover 17 Genes Related to Brain Disorders

DANVILLE, Pa., Jan. 27, 2016 /PRNewswire-USNewswire/ — A recent study led by a team of researchers at Geisinger Health System’s Autism & Developmental Medicine Institute (ADMI) identified 17 new genes causing autism and other related brain disorders, including intellectual disability/developmental delay, epilepsy, attention deficit hyperactivity disorder, schizophrenia, and bipolar disorder. …

Read More »

Lilly and Roche Diagnostics Partner on Alzheimer’s Disease Adjunct Diagnostic Tool

INDIANAPOLIS, Jan. 27, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42. Together with tau tangles, the presence of amyloid in the brain is a key marker …

Read More »

Alkermes Initiates Clinical Testing of its Alzheimer’s Disease Drug Candidate

DUBLIN–(BUSINESS WIRE)–Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients with Alzheimer’s disease (AD) and other central nervous system (CNS) indications. The double-blind, placebo-controlled study will evaluate the …

Read More »

OncoGenex’s NSCLC Candidate Fails to Meet PFS Goal in Mid-Stage Trial

BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 20, 2016 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced today that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required …

Read More »

FDA Grants Breakthrough Therapy Designation to AbbVie’s Chronic Lymphocytic Leukemia Drug

NORTH CHICAGO, Ill., Jan. 20, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Venetoclax is an inhibitor …

Read More »

Boehringer Ingelheim Inks $262 Million CNS Deal with Arena Pharmaceuticals

INGELHEIM, Germany, and SAN DIEGO, Jan. 12, 2016 /PRNewswire/ — Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS …

Read More »

New Report Finds Prescription Drug Prices Rose 10.43 Percent in 2015

NEW YORK–(BUSINESS WIRE)–Amidst increasing consumer concerns and mounting scrutiny from lawmakers, a new report indicates prescription drug prices rose 10.43 percent in 2015 – continuing to squeeze American household budgets and adding fuel to the debate surrounding soaring healthcare costs. The figures were released as part of the OneRx® National …

Read More »

Immune Pharmaceuticals Licenses Bispecific Antibody Technology from Atlante Biotech

NEW YORK, Dec. 28, 2015 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific …

Read More »

AstraZeneca’s Zurampic Receives FDA Approval for Patients with Gout

22 December 2015 AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved ZURAMPIC® (lesinurad) 200mg tablets in combination with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with an …

Read More »

FDA Approves Actelion’s Uptravi for Pulmonary Arterial Hypertension

ALLSCHWIL, SWITZERLAND – 22 December 2015 – Actelion (SIX: ATLN) announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku, for the treatment of pulmonary arterial hypertension …

Read More »